Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.

You may also be interested in...



Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns

Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.

Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns

Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.

Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment

FDA may place more faith in physician diligence to read updated labeling as it manages the risk for Eli Lilly's Cymbalta in some chronic pain indications

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel